TP53 and cancer: Taken together, these results suggest that despite the wild-type p53 protein status in most UMs, alterations affecting the pathway (i.e., p53 stabilization and activation of downstream targets) or imbalanced expression of the shorter p53 isoforms may influence cancer aggressiveness and response to anti-cancer therapies in UM.